{"filing":{"accession_number":"0001815776-26-000041","cik":"0001815776","ticker":"LENZ","company_name":"LENZ Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"lenz-20260612.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577626000041/lenz-20260612.htm"},"events":[{"id":10853,"run_id":9522,"accession_number":"0001815776-26-000041","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from LENZ Therapeutics' 2026 annual meeting held on June 12, 2026. The filing reports voting outcomes for two matters: (1) election of three Class II directors (Evert Schimmelpennink, Jeff George, and Shelley Thunen), and (2) ratification of Ernst \u0026 Young LLP as independent auditor. The tabulated vote counts for each nominee and proposal are the core content of Item 5.07, which is the standard Item for reporting annual meeting results.","company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":7274,"accession_number":"0001815776-26-000041","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from LENZ Therapeutics' 2026 annual meeting held on June 12, 2026. The filing reports voting outcomes for two matters: (1) election of three Class II directors (Evert Schimmelpennink, Jeff George, and Shelley Thunen), and (2) ratification of Ernst \u0026 Young LLP as independent auditor. The tabulated vote counts for each nominee and proposal are the core content of Item 5.07, which is the standard Item for reporting annual meeting results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:21:58.549709+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7274,"accession_number":"0001815776-26-000041","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from LENZ Therapeutics' 2026 annual meeting held on June 12, 2026. The filing reports voting outcomes for two matters: (1) election of three Class II directors (Evert Schimmelpennink, Jeff George, and Shelley Thunen), and (2) ratification of Ernst \u0026 Young LLP as independent auditor. The tabulated vote counts for each nominee and proposal are the core content of Item 5.07, which is the standard Item for reporting annual meeting results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:21:58.549709+00:00","company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","filing_date":"2026-06-12"}]}